Lv51
1120 积分 2024-04-25 加入
I018 TT-P34: a novel first-in-class peptide drug for treatment of Huntington’s Disease
21天前
已完结
Adrenomedullin - new perspectives of a potent peptide hormone
2个月前
已完结
Adrenomedullin improved endothelial dysfunction via receptor-Akt pathway in rats with obesity-related hypertension
2个月前
已完结
Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis
2个月前
已完结
Adrenomedullin – Current perspective on a peptide hormone with significant therapeutic potential
2个月前
已完结
Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility
5个月前
已完结
The role of phospholipase A2-derived mediators in obesity
5个月前
已完结
Platelet Activating Factor (PAF): A Mediator of Inflammation
5个月前
已完结
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart
5个月前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
